Dyne Therapeutics vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Dyne Therapeutics Inc (DYN)

Q3 202617 Jun – 12 Aug 2026

▲3

Dyne advances DMD drug toward FDA decision, funds pipeline

FDA accepts DMD drug application with priority review The FDA accepted Dyne's application for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, with a decision expected by January 21, 2027. This is a major step toward a potential U.S. launch in early 2027, boosting investor confidence in the company's lead program.
This is the most significant regulatory milestone that directly affects DYN's path to revenue and is new information.
New FSHD drug program cleared for human testing Dyne received FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). This expands the company's pipeline into a third disease area, showing the platform's broader potential and adding another shot at future growth.
This is a new pipeline expansion that increases the company's long-term value proposition.
Company raises $375 million in stock sale, diluting shareholders Dyne priced an upsized $375 million public offering at $20.50 per share, which will fund its pipeline but dilutes existing shareholders. The stock fell 10.6% after the announcement, reflecting the near-term cost of raising capital for long-term goals.
This is a major capital event that affects the share count and near-term stock price, and is new information.
Expanded debt facility adds up to $400 million for launches Dyne expanded its debt facility with Hercules Capital to up to $400 million, providing non-dilutive funding to advance its lead candidates toward potential launches. This strengthens the balance sheet without selling more shares, supporting the company's commercial preparations.
This is a new financing event that improves liquidity and reduces reliance on equity dilution.

July 202617 Jun – 12 Aug 2026

▲3

Dyne advances DMD drug toward FDA decision, funds pipeline

FDA accepts DMD drug application with priority review The FDA accepted Dyne's application for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, with a decision expected by January 21, 2027. This is a major step toward a potential U.S. launch in early 2027, boosting investor confidence in the company's lead program.
This is the most significant regulatory milestone that directly affects DYN's path to revenue and is new information.
New FSHD drug program cleared for human testing Dyne received FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). This expands the company's pipeline into a third disease area, showing the platform's broader potential and adding another shot at future growth.
This is a new pipeline expansion that increases the company's long-term value proposition.
Company raises $375 million in stock sale, diluting shareholders Dyne priced an upsized $375 million public offering at $20.50 per share, which will fund its pipeline but dilutes existing shareholders. The stock fell 10.6% after the announcement, reflecting the near-term cost of raising capital for long-term goals.
This is a major capital event that affects the share count and near-term stock price, and is new information.
Expanded debt facility adds up to $400 million for launches Dyne expanded its debt facility with Hercules Capital to up to $400 million, providing non-dilutive funding to advance its lead candidates toward potential launches. This strengthens the balance sheet without selling more shares, supporting the company's commercial preparations.
This is a new financing event that improves liquidity and reduces reliance on equity dilution.

Latest17 Jun – 12 Aug 2026

▲3

Dyne advances DMD drug toward FDA decision, funds pipeline

FDA accepts DMD drug application with priority review The FDA accepted Dyne's application for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, with a decision expected by January 21, 2027. This is a major step toward a potential U.S. launch in early 2027, boosting investor confidence in the company's lead program.
This is the most significant regulatory milestone that directly affects DYN's path to revenue and is new information.
New FSHD drug program cleared for human testing Dyne received FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). This expands the company's pipeline into a third disease area, showing the platform's broader potential and adding another shot at future growth.
This is a new pipeline expansion that increases the company's long-term value proposition.
Company raises $375 million in stock sale, diluting shareholders Dyne priced an upsized $375 million public offering at $20.50 per share, which will fund its pipeline but dilutes existing shareholders. The stock fell 10.6% after the announcement, reflecting the near-term cost of raising capital for long-term goals.
This is a major capital event that affects the share count and near-term stock price, and is new information.
Expanded debt facility adds up to $400 million for launches Dyne expanded its debt facility with Hercules Capital to up to $400 million, providing non-dilutive funding to advance its lead candidates toward potential launches. This strengthens the balance sheet without selling more shares, supporting the company's commercial preparations.
This is a new financing event that improves liquidity and reduces reliance on equity dilution.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 202620 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.

August 202620 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest20 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.